Key Highlights

  • The FDA cleared Processa's IND application for VT-7208 in chronic spontaneous urticaria, enabling a planned multicenter Phase 2 study in approximately 120 adults with moderate-to-severe disease inadequately controlled by antihistamines.
  • Processa entered a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance a novel oral macrocyclic peptide-based neonatal Fc receptor antagonist program targeting IgG-mediated autoimmune diseases.
  • Sheila Gujrathi, M.D., co-founder and executive chair of Vidya Therapeutics and a physician-scientist with extensive immunology and oncology Drug Development experience, was appointed Executive Chair of Processa's board of directors.
  • Cash resources, including approximately $200 million raised in a private Placement alongside the Vidya acquisition, are expected to fund operations into the second half of 2029.

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage pharmaceutical company that acquired Vidya Therapeutics in June 2026, provided a corporate and pipeline progress update covering three developments: clearance of an investigational new drug application from the US Food and Drug Administration for its lead asset VT-7208 in chronic spontaneous urticaria, a new research collaboration with Generian Pharmaceuticals to expand its immunology pipeline, and the appointment of Sheila Gujrathi as Executive Chair of the board. Together, the announcements represent the company's early execution following a transaction that brought in new leadership, a new lead asset, and approximately $200 million in fresh Capital from leading institutional healthcare investors.

FDA IND Clearance Clears Path for Phase 2 CSU Study

VT-7208 is a next-generation, CNS-penetrant, once-daily oral Bruton's tyrosine kinase inhibitor designed to address immune-mediated diseases. Phase 1 development has been completed, and the FDA's clearance of the IND in chronic spontaneous urticaria enables the company to move directly into a Phase 2 proof-of-concept study. The planned trial is a multicenter, randomized, double-blind, placebo-controlled study expected to enroll approximately 120 adults with moderate-to-severe CSU whose disease is not adequately controlled with H1 antihistamines. The study will evaluate VT-7208 against placebo over 12 weeks, with efficacy, safety, tolerability, and pharmacologic activity as assessment objectives.

CSU is a chronic inflammatory disease characterized by recurrent hives and swelling without an identifiable external trigger, affecting an estimated 1.6 to 2 million US adults. Processa cited a meaningful proportion of patients who remain inadequately controlled despite available therapies, including the approved anti-IgE and anti-IL-4/13 biologics, as the basis for pursuing an oral BTK inhibitor in this setting. The CNS-penetrant profile of VT-7208 also distinguishes it from earlier BTK inhibitors developed for oncology applications, potentially offering advantages in diseases where central nervous system immune modulation may be relevant.

Generian Collaboration Adds Oral FcRn Antagonist to Portfolio

Alongside the CSU IND clearance, Processa announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals, a UPMC Enterprises portfolio company that emerged from the UPMC/University of Pittsburgh scientific ecosystem. The collaboration centers on a novel oral macrocyclic peptide-based neonatal Fc receptor antagonist program targeting IgG-mediated autoimmune diseases — a clinically validated mechanism that is currently addressed primarily by injectable therapies including rozanolixizumab and efgartigimod.

Processa's strategy with the Generian deal is to expand its pipeline around a second immune target using a capital-efficient licensing and collaboration structure, rather than acquiring a development-stage company outright. The oral macrocyclic peptide format is designed to deliver systemic FcRn antagonism through a pill rather than an infusion or subcutaneous injection, a format that would complement VT-7208 and potentially address a different segment of the IgG-autoimmune disease market. Processa holds an exclusive option to advance the program following the collaboration phase.

Gujrathi as Executive Chair; Cash Runway Extends to 2029

Sheila Gujrathi, M.D., has been appointed Executive Chair of Processa's board, stepping up from the board role she held since the Vidya acquisition. A physician-scientist and biotechnology entrepreneur, Gujrathi previously served as Executive Chair of Ventyx Biosciences, Chair of Turning Point Therapeutics and ADARx Pharmaceuticals, co-founder and CEO of Gossamer Bio, and Chief Medical Officer of Receptos. In the Executive Chair role she will support management on corporate strategy, capital allocation, and organizational development. She was a founder of Vidya Therapeutics, giving her direct knowledge of the VT-7208 asset and its development history.

The approximately $200 million private placement that accompanied the Vidya acquisition, combined with operating efficiencies from the integration, gives Processa a cash position management expects to fund operations into the second half of 2029 — a runway of more than three years that provides time to run Phase 2 studies in CSU and potentially initiate or advance Phase 2 programs in food allergy and relapsing multiple sclerosis, the company's other two planned VT-7208 indications.

Processa enters the fourth quarter of 2026 with a lead asset cleared to enter Phase 2 in three separate indications, a new pipeline collaboration focused on a complementary immune target, an experienced board Leadership structure, and a funded runway extending well into the next decade. The company's near-term agenda will center on activating the CSU trial, establishing study sites and beginning patient screening, while advancing the food allergy and relapsing MS protocols. The milestones that matter most for shareholders will be Phase 2 enrollment completion and the first interim data readouts from VT-7208 — timelines that are not yet disclosed publicly.